Abstract:Purpose: Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer.
Many of these mutations have been identified as oncogenic drivers in a wide array of cancer types
and can be classified into three Classes according to molecular characteristics. Consensus
treatment strategies for Class 2 and 3 BRAF mutations have not yet been established.
Methods: We performed a systematic review and meta-analysis of individual patient data to assess
treatment outcomes with FDA-approved mitogen activated p… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.